Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Losartan Potassium NDC 68788-8186 by Preferred Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Losartan Potassium Tab USP 100mg - C4B81F90 BCD0 45D0 99CE 35CA998D473A 00
Losartan is a prescription medication used to treat high blood pressure. The drug comes in the form of tablet and contains 100mg of Losartan potassium. It is manufactured by Solco Healthcare U.S., LLC and is a generic version of Cozaar. The package size and expiration date are also mentioned. The medication should not be transferred to anyone other than the patient it was prescribed for, as it is prohibited by federal law.*
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
This appears to be a comparison between two medications - Atenolol and Losartan Potassium - in terms of their effectiveness in reducing the risk of an unspecified primary endpoint. The text mentions an adjusted risk reduction of 13% with a p-value of 0.021, implying that Losartan Potassium may be more effective than Atenolol. The graph shows the study month timeline from 0 to 66, indicating that the study was conducted for at least 5 years.*
Figure 2 - spl image3 figure2
This text provides information about the adjusted risk reduction of a medication called Atenolol and its equivalence to another medication called Losartan Potassium. The risk reduction percentage is shown to be 25% with a p-value of 0.001. Additionally, there is a graph that indicates the percentage of patients with fatal/non-fatal stroke at different study months ranging from 6 to 66.*
Figure 3 - spl image4 figure3
The text describes the results of a clinical trial regarding the primary endpoint events within demographic subgroups. The trial evaluated the effectiveness of Losartan potassium compared to Atenolol on stroke prevention in patients. The results are presented in a table that includes the number of events, patient rates, and hazard ratios for different subgroups (based on age, gender, race, ISH, diabetes, and history of CVD). The symbols in the table are proportional to the sample size. The study was adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 - spl image5 figure4
This is a graph showing the percentage of patients experiencing an event while taking Losartan Potassium versus Placebo over a period of 48 months. The Risk Reduction for Losartan Potassium is 16.1%, with a p-value of 0.022. There are no other readable details available.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
